{"nctId":"NCT01223352","briefTitle":"Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension","startDateStruct":{"date":"2011-03-08","type":"ACTUAL"},"conditions":["Pulmonary Arterial Hypertension"],"count":64,"armGroups":[{"label":"Bosentan 2 mg/Kg t.i.d.","type":"EXPERIMENTAL","interventionNames":["Drug: bosentan"]},{"label":"Bosentan 2 mg/Kg b.i.d.","type":"EXPERIMENTAL","interventionNames":["Drug: bosentan"]}],"interventions":[{"name":"bosentan","otherNames":["Tracleer","ACT-050088"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. PAH diagnosis confirmed with right heart catheterization (RHC):\n\n   * Idiopathic or heritable PAH, or\n   * Associated PAH persisting after complete repair of a congenital heart defect (PAH has to be persistent for at least 6 months after surgery) or\n   * PAH-Congenital Heart Disease (PAH-CHD) associated with systemic-to-pulmonary shunts (after global amendment dated 09 May 2012)\n2. World Health Organization functional Class (WHO FC) I, II or III\n3. Male or female ≥ 3 months and \\< 12 years of age (maximum age at randomization is 11.5 years)\n4. Body weight ≥ 3.5 kg\n5. Peripheral oxygen saturation (SpO2) ≥ 88% (at rest, on room air)\n6. Baseline PAH-therapy (Calcium channel blocker, bosentan, prostanoid, phosphodiesterase type-5 inhibitor) if present, has to be stable for at least 3 months prior to screening. During the study, all background treatments should remain stable\n7. Signed informed consent by the parents or legal representatives\n\nExclusion Criteria:\n\n1. PAH etiologies other than listed above\n2. Non-stable disease status\n3. Need or plan to wean patient from intravenous epoprostenol or intravenous or inhaled iloprost\n4. Systolic blood pressure \\< 80% of the lower limit of normal range\n5. Aspartate aminotransferase and/or alanine aminotransferase values \\> 1.5 times the upper limit of normal range.\n6. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C\n7. Hemoglobin and/or hematocrit levels \\< 75% of the lower limit of normal range.\n8. Known intolerance or hypersensitivity to bosentan or any of the excipients of the dispersible Tracleer tablet\n9. Treatment with forbidden medication within 2 weeks or at least 5 times the half-life prior to randomization, whichever is the longest:\n\n   * Glibenclamide (glyburide)\n   * Cyclosporin A\n   * Sirolimus\n   * Tacrolimus\n   * Fluconazole\n   * Rifampicin (rifampin)\n   * Ritonavir\n   * Co-administration of CYP2C9 inhibitors (e.g., amiodarone, voriconazole) and moderate/strong CYP3A4 inhibitors (e.g., amprenavir, erythromycin, ketoconazole, diltiazem, itraconazole)\n   * Endothelin receptor antagonists (ERAs) other than bosentan\n10. Treatment with another investigational drug within 1 month prior to randomization or planned treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Months","maximumAge":"12 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan","description":"Daily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours \\[AUC(0-24)\\].\n\nConcentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau, which is the AUC over a dosing interval (AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen). As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) \\[AUC(0-24c)\\].","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7275.1","spread":null},{"groupId":"OG001","value":"8535.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Dose-corrected Maximum Plasma Concentration [Cmaxc] of Bosentan","description":"Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively.\n\nThe peak plasma concentration (Cmax) of bosentan was directly obtained from the measured plasma concentrations and was dose-corrected to the target dose of 2 mg/kg (Cmaxc).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"527.9","spread":null},{"groupId":"OG001","value":"742.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Reach Cmax [Tmax] of Bosentan","description":"Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively.\n\ntmax was obtained directly from the measured plasma concentrations.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan Metabolites (Ro 478634, Ro 485033, Ro 641056)","description":"Concentrations of the metabolites were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. Daily exposure to the metabolites corresponds to the area under the concentration-time curve \\[AUC(0-24)\\] of the corresponding metabolite over a period of 24 hours, and was calculated in the same manner as the primary endpoint. AUC(0-24c) was corrected to 2 mg/kg (target dose) \\[AUC(0-24c)\\].","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173.2","spread":null},{"groupId":"OG001","value":"200.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"968.8","spread":null},{"groupId":"OG001","value":"1352.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"716.2","spread":null},{"groupId":"OG001","value":"1014.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in WHO Functional Class at End of Study","description":"The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension (PH):\n\nClass I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class IIII (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms.\n\nNumber of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Global Clincial Impression Scale (GCIS) at End of Study","description":"The GCIS is an assessment tool providing a single global assessment of the patient's current overall clinical condition: Very Good, Good, Neither Good or Bad, Bad and Very Bad. The assessment was performed both by the physician and the parents / legal representatives independently. Global clinical impression (GCI) at end of study was compared to GCI at baseline and the number of patients with clinical condition considered as worsened, improved or unchanged are determined.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Treatment-emergent Liver Function Abnormalities","description":"Number of patients with increase in alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN). The worst post-baseline value was considered. The treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Treatment-emergent Hemoglobin Abnormalities","description":"Number of patients with marked hemoglobin decreases (absolute values below 10 g/dL). The worst post-baseline value was considered.\n\nThe treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":31},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","PYREXIA","NASOPHARYNGITIS","DIARRHOEA","VOMITING"]}}}